Provigil FDA Approval History

The 1998 Narcolepsy Approval

Modafinil received its first FDA approval on December 24, 1998 under NDA 020717, granted to Cephalon, Inc. for the treatment of excessive daytime sleepiness associated with narcolepsy. The approval made Provigil the first non-amphetamine wakefulness-promoting agent cleared for this indication in the United States.

The key evidence came from two randomized, double-blind, placebo-controlled trials conducted by the US Modafinil in Narcolepsy Multicenter Study Group. The first trial, published in Annals of Neurology in 1998, enrolled 283 patients with narcolepsy and demonstrated that modafinil 200 mg and 400 mg significantly improved wakefulness on the Maintenance of Wakefulness Test (MWT) and reduced excessive sleepiness on the Epworth Sleepiness Scale (ESS) compared to placebo (1). Mean MWT sleep latency improved by approximately 2 minutes over placebo at both doses, a modest but statistically significant effect (P<0.001). A confirmatory second trial showed similar results, and the FDA's review noted a favorable side-effect profile relative to existing stimulant options like dextroamphetamine and methylphenidate (2).

Cephalon marketed Provigil specifically as a Schedule IV controlled substance, a classification that reflected lower abuse potential compared to Schedule II amphetamines. This scheduling distinction gave Provigil a commercial and clinical advantage: prescribers could phone in refills, and the regulatory burden on pharmacies was lighter.

2004 Label Expansion: OSAHS and Shift-Work Disorder

In January 2004, the FDA approved two supplemental indications for Provigil, expanding its labeled uses to include excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift-work sleep disorder (SWSD). These approvals broadened modafinil's addressable patient population considerably.

The OSAHS approval was based on a 12-week randomized controlled trial of 327 patients with residual excessive sleepiness despite adequate continuous positive airway pressure (CPAP) therapy. Modafinil 200 mg or 400 mg improved mean ESS scores from approximately 16 (severe sleepiness) to 12 (moderate), compared to minimal change with placebo. The FDA label specifies that modafinil is an adjunct to CPAP, not a replacement, and that clinicians should ensure underlying airway obstruction is being treated before prescribing (3).

For SWSD, a separate trial in 209 patients working night or rotating shifts showed that modafinil 200 mg taken before the start of a shift improved Clinical Global Impression of Change scores and reduced lapses on psychomotor vigilance testing. The approval addressed a real clinical gap. Few pharmacological options existed for shift-workers struggling with alertness during non-traditional hours.

DEA Scheduling and Abuse Potential Classification

Modafinil was placed into Schedule IV of the Controlled Substances Act at the time of its 1998 approval, reflecting the FDA and DEA's assessment of relatively low abuse liability. This scheduling decision was informed by preclinical and clinical pharmacology data showing that modafinil's mechanism of action differs from traditional psychostimulants.

Unlike amphetamines, modafinil does not primarily act through catecholamine release. Its precise mechanism remains incompletely understood, but evidence points to selective activation of hypothalamic wake-promoting centers, involvement of the dopamine transporter (DAT), and modulation of GABA/glutamate balance in sleep-wake circuits (4). In human abuse-liability studies, modafinil produced lower subjective ratings of "euphoria" and "drug liking" compared to methylphenidate and dextroamphetamine at equivalent wake-promoting doses.

Schedule IV classification means modafinil carries prescribing restrictions (limited refills, controlled-substance monitoring in some states) but far fewer barriers than Schedule II agents. Prescriptions can typically be called in or electronically transmitted. The DEA classification has remained unchanged since 1998, despite periodic discussions about off-label use in healthy individuals seeking cognitive enhancement.

The 2006 Pediatric Rejection

Cephalon submitted a supplemental NDA seeking approval of modafinil for attention deficit hyperactivity disorder (ADHD) in pediatric patients. An FDA advisory committee reviewed the application in March 2006 and voted against approval.

The rejection hinged on safety. During clinical trials, one pediatric patient developed a serious skin reaction consistent with erythema multiforme and suspected Stevens-Johnson syndrome (SJS). Given that SJS can be fatal and that the ADHD population included millions of children for whom multiple approved alternatives existed, the advisory committee concluded that the risk-benefit ratio was unfavorable (5). The committee voted 12-1 against recommending approval.

This decision had lasting consequences. Cephalon withdrew its pediatric ADHD application. The FDA subsequently required stronger dermatologic safety language in the Provigil label, and the 2006 rejection effectively closed the door on modafinil's largest potential market expansion.

2007 Safety Labeling: Serious Skin Reactions and Psychiatric Symptoms

In 2007, the FDA mandated significant safety labeling changes for Provigil. These changes addressed two categories of concern that had emerged from post-marketing surveillance and the pediatric trial experience.

The first update added prominent warnings about serious dermatologic reactions, including SJS, toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS). The label now states that modafinil should be discontinued at the first sign of rash unless the rash is clearly not drug-related. Post-marketing reports had identified cases of hospitalization and at least one case requiring skin grafting (3).

The second update addressed psychiatric adverse events. Reports of anxiety, mania, hallucinations, and suicidal ideation in patients taking modafinil prompted the FDA to add warnings about psychiatric symptoms. The label instructs prescribers to evaluate patients for a history of psychosis, depression, or mania before initiating therapy and to monitor for emergence of psychiatric symptoms during treatment.

Dr. Russell Katz, then Director of the FDA's Division of Neurology Products, stated in a 2007 FDA communication: "Patients and physicians should be aware that modafinil may cause serious side effects, including serious rashes and serious allergic reactions that may result in hospitalization" (6).

Generic Entry and Patent Settlements

Provigil's exclusivity story is inseparable from the patent-settlement controversies that defined pharmaceutical competition law in the late 2000s. Cephalon held multiple patents on modafinil, with key patents set to expire as late as 2012.

Several generic manufacturers, including Barr Pharmaceuticals, Teva, Mylan, and Ranbaxy, filed Abbreviated New Drug Applications (ANDAs) challenging Cephalon's patents under Paragraph IV of the Hatch-Waxman Act. Between 2005 and 2006, Cephalon settled with all four challengers. The settlements were widely scrutinized as potential "pay-for-delay" agreements, in which the brand-name manufacturer compensates generic companies to delay market entry (7).

The Federal Trade Commission (FTC) filed an antitrust complaint against Cephalon in 2008, alleging that these settlements cost consumers and the healthcare system hundreds of millions of dollars in delayed access to cheaper generics. The case was eventually settled in 2015, after Teva (which had acquired Cephalon in 2011) agreed to pay $1.2 billion to resolve FTC and class-action claims.

Generic modafinil reached the US market in 2012. Multiple ANDA holders now manufacture the drug. Average generic prices dropped substantially from Provigil's branded peak of roughly $10-15 per tablet to under $1 per tablet at many pharmacies.

Armodafinil and the Nuvigil Transition

Even before generic entry, Cephalon had prepared a successor product. Nuvigil (armodafinil), the R-enantiomer of modafinil, received FDA approval in June 2007 for the same three indications: narcolepsy, OSAHS-related excessive sleepiness, and SWSD (8).

Armodafinil's approval was based on clinical trials showing efficacy comparable to racemic modafinil, with a longer half-life that might sustain late-day wakefulness more effectively. Peak plasma concentrations of armodafinil occur later (approximately 2 hours post-dose versus 2-4 hours for modafinil), and the 150 mg armodafinil dose was positioned as roughly equivalent to 200 mg modafinil.

Cephalon undertook an aggressive brand-switch campaign from Provigil to Nuvigil, converting patients before generic modafinil became available. This strategy was common among pharmaceutical companies facing patent cliffs. The campaign drew criticism from payers and formulary committees, who noted the absence of head-to-head superiority data for armodafinil over modafinil.

Current Regulatory Status and Ongoing Surveillance

As of 2026, modafinil remains an FDA-approved, Schedule IV wakefulness-promoting agent with three labeled indications. The drug's regulatory status has been stable since the 2007 labeling revisions, with only minor label updates in subsequent years.

The FDA Adverse Event Reporting System (FAERS) continues to collect post-marketing safety data. Periodic safety reviews have not triggered additional major label changes beyond those already implemented. The most commonly reported adverse events in FAERS remain headache, nausea, anxiety, and insomnia, consistent with the clinical trial database (9).

Off-label prescribing remains prevalent. Modafinil is commonly used for fatigue associated with multiple sclerosis, cancer-related fatigue, and cognitive enhancement in healthy individuals. A 2017 Cochrane review examining modafinil for cognitive function found limited and low-quality evidence supporting cognitive benefits in non-sleep-deprived healthy adults, cautioning against routine off-label use for enhancement purposes (10).

Internationally, the European Medicines Agency (EMA) restricted modafinil's approved indication to narcolepsy only in 2010, removing the OSAHS and SWSD indications that remain on the US label. The EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of modafinil in these conditions did not outweigh the risks, particularly cardiovascular and dermatologic safety concerns (11).

The Label Today: What Prescribers Need to Know

The current Provigil prescribing information runs 27 pages. Several sections deserve particular attention from prescribers in 2026.

The Warnings and Precautions section lists serious rash (including SJS/TEN), angioedema and anaphylaxis, multi-organ hypersensitivity reactions, and psychiatric symptoms as the primary safety concerns. Prescribers must inform patients to discontinue modafinil and seek immediate medical attention if they develop a skin rash, hives, mouth sores, or blistering. A history of modafinil-associated rash is a contraindication to rechallenge (3).

Drug interactions are clinically relevant. Modafinil induces CYP3A4 and may reduce the effectiveness of hormonal contraceptives (oral, patch, ring). The label explicitly warns that alternative or additional contraception is recommended during therapy and for one month after discontinuation. Modafinil also inhibits CYP2C19, potentially increasing levels of drugs like omeprazole, phenytoin, and diazepam.

The recommended dose is 200 mg once daily in the morning for narcolepsy and OSAHS, or one hour before the start of a work shift for SWSD. Doses above 200 mg have not demonstrated additional benefit in clinical trials, though the 400 mg dose is sometimes used off-label. Hepatic impairment requires dose reduction to 100 mg daily.

For prescribers evaluating patients in 2026, the modafinil label's CYP3A4 induction warning regarding hormonal contraceptives remains one of the most clinically consequential drug interactions in sleep medicine, requiring documentation and patient counseling at every prescribing encounter.